Spectrum Pharma (SPPI) Tops Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Spectrum Pharma (SPPI) Tops Q3 EPS by 5c

Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results

November 8, 2018 4:00 PM EST

Poziotinib interim data from the MD Anderson Phase 2 study presented in Q3 demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutations in NSCLC patients Spectrum has submitted a request for Breakthrough Therapy Designation (BTD) for poziotinib and expects a response from the FDA by end of the year Enrollment of the EGFR, previously treated cohort in the poziotinib ZENITH20 trial is expected to be completed by first quarter of 2019 ROLONTIS® (eflapegrastim) Biologics License Application (BLA) filing is expected by the end of the year... More